Multisite Validation of a Functional Assay to Adjudicate SCN5A Brugada Syndrome-Associated Variants.
Ma JG. et al, (2024), Circ Genom Precis Med, 17
A Promoter Deletion Confirms That MYBPC3 Haploinsufficiency Is Sufficient to Cause Hypertrophic Cardiomyopathy in Humans.
Hayesmoore JBG. et al, (2024), Circ Genom Precis Med, 17
The penetrance of rare variants in cardiomyopathy-associated genes: A cross-sectional approach to estimating penetrance for secondary findings.
McGurk KA. et al, (2023), Am J Hum Genet, 110, 1482 - 1495
EMQN: Recommendations for genetic testing in inherited cardiomyopathies and arrhythmias.
Hayesmoore JB. et al, (2023), Eur J Hum Genet, 31, 1003 - 1009
Public and patient involvement in research to support genome services development in the UK
Hunter A. et al, (2023), Journal of Translational Genetics and Genomics, 7, 17 - 26
The Genetic Basis of Primary Cardiomyopathies in Childhood: Implications for Clinical Genetic Testing.
Thomson KL. and Ormondroyd E., (2022), Circ Genom Precis Med, 15
A calibrated functional patch-clamp assay to enhance clinical variant interpretation in KCNH2-related long QT syndrome.
Jiang C. et al, (2022), Am J Hum Genet
Incremental value of left atrial booster and reservoir strain in predicting atrial fibrillation in patients with hypertrophic cardiomyopathy: a cardiovascular magnetic resonance study.
Raman B. et al, (2021), J Cardiovasc Magn Reson, 23
Data-driven modelling of mutational hotspots and in silico predictors in hypertrophic cardiomyopathy.
Waring A. et al, (2021), J Med Genet, 58, 556 - 564
Harmonizing the Collection of Clinical Data on Genetic Testing Requisition Forms to Enhance Variant Interpretation in Hypertrophic Cardiomyopathy (HCM): A Study from the ClinGen Cardiomyopathy Variant Curation Expert Panel
Morales A. et al, (2021), Journal of Molecular Diagnostics, 23, 589 - 598
Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity.
Harper AR. et al, (2021), Nat Genet, 53, 135 - 142
Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity.
Harper AR. et al, (2021), Nat Genet, 53, 135 - 142
Hypertrophic Cardiomyopathy: Genetic Testing and Risk Stratification.
Stafford F. et al, (2021), Curr Cardiol Rep, 23
Secondary findings in inherited heart conditions: a genotype-first feasibility study to assess phenotype, behavioural and psychosocial outcomes.
Ormondroyd E. et al, (2020), Eur J Hum Genet, 28, 1486 - 1496
Publisher Correction: Whole-genome sequencing of a sporadic primary immunodeficiency cohort.
Thaventhiran JED. et al, (2020), Nature, 584
Whole-genome sequencing of a sporadic primary immunodeficiency cohort.
Thaventhiran JED. et al, (2020), Nature, 583, 90 - 95
Whole-genome sequencing of patients with rare diseases in a national health system.
Turro E. et al, (2020), Nature, 583, 96 - 102
An assessment of the role of vinculin (VCL) loss of function variants in inherited cardiomyopathy.
Hawley MH. et al, (2020), Hum Mutat
Reevaluation of the South Asian MYBPC3Δ25bp Intronic Deletion in Hypertrophic Cardiomyopathy.
Harper AR. et al, (2020), Circ Genom Precis Med, 13